Nanogen gets patent for enhancing molecular reactions:
This article was originally published in Clinica
Executive Summary
Molecular and POC diagnostic products maker Nanogen has received a US patent relating to a technology that enables control over a wide range of molecular reactions involved in molecular analyses and diagnostics, including nucleic acid hybridisation and amplification, antibody and antigen reactions. The system described in the patent is at the core of Nanogen's electronic microarray technology, which uses electricity to move and concentrate biological samples in miniature formats for diagnostic applications. It greatly enhances the rate and specificity of the molecular biological reaction, said the San Diego, California firm.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.